This letter describes the first demonstration of clinical response to the anti-EGFR inhibitor gefitinib in a case of urothelial carcinoma of the renal pelvis harboring a rare EGFR double mutation. New mutations and unexpected clinical responses should be always explored through wide-spectrum mutational analyses.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3983821 | PMC |
| http://dx.doi.org/10.1634/theoncologist.2013-0346 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[Detection and interpretation of PD-L1 in urologic neoplasms].
Zhonghua Bing Li Xue Za Zhi
January 2025
Department of Pathology, School of Basic Medical Sciences, Third Hospital, Peking University Health Science Center, Beijing100191, China.
Immune checkpoint inhibitors targeting PD-1/PD-L1 are gradually being applied in the treatment of advanced urinary system tumors. Immunohistochemical analysis of PD-L1 expression is the most popular method for screening suitable patients for immunotherapy and predicting therapeutic efficacy. The current application status of PD-L1 detection for urinary system tumors (mainly urothelial carcinoma), methods of the different antibody tests and the precautions, challenges and solutions in the interpretation of immunostaining were summarized in this review.
View Article and Find Full Text PDFLethal clinical outcome and chemotherapy and immunotherapy resistance in patients with urothelial carcinoma with MDM2 amplification or overexpression.
J Immunother Cancer
January 2025
NHC Key Laboratory of Glycoconjugate Research, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, Shanghai, China
Background: The E3 ubiquitin ligase murine double minute 2 (MDM2) binds the p53 transcriptional activation domain and acts as a potent inhibitor of pathway, one of the three most crucial oncogenic pathways in urothelial carcinoma (UC). However, the clinical significance and impact on tumor immune contexture of amplification in UC remain unclear.
Methods: This study analyzed 240 patients with UC with matched clinical annotations from two local cohorts (ZSHS cohort and FUSCC cohort).
We studied the effect of urinary urea concentration on the hemolysin production and cytotoxicity of the uropathogenic Morganella morganii strain MM 190. The highest hemolytic activity of M. morganii cultivated in urine with low urea concentration (23 and 82 mmol/liter) was observed between 3rd and 4th hours of post-inoculation, while in urine with standard urea level (117 mmol/liter), the activity was observed at 5th hour of post-inoculation.
View Article and Find Full Text PDFClinical Utility of Serial Circulating Tumor DNA Analysis as a Minimally Invasive Biomarker in Advanced Urothelial Cancer.
JCO Precis Oncol
January 2025
Department of Urology, Kyoto University School of Medicine, Kyoto, Japan.
Purpose: Circulating tumor DNA (ctDNA) analysis is an alternative to tissue biopsy for genotyping in various cancers. We aimed to establish a plasma ctDNA sequencing assay, then evaluate its clinical utility in advanced urothelial cancer (UC).
Materials And Methods: This study included 82 patients with muscle-invasive or metastatic UC.
Clinical Outcomes of Micropapillary Urothelial Carcinoma of the Bladder Treated With Radical Cystectomy.
Cancer Diagn Progn
January 2025
Department of Urology, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan.
Background/aim: This study examined the treatment outcomes of radical cystectomy (RC) for micropapillary subtype (MPS) bladder cancer treated at our hospital.
Patients And Methods: Histopathological findings of RC specimens collected from 2003 to 2020 were evaluated. Recurrence-free survival (RFS) and overall survival (OS) after RC, as well as the efficacy of chemotherapy in cases of recurrence, were retrospectively assessed.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!